| Theme | Diagnostic Strategy for Early Stage Pancreatic Cancer | |
|---|---|---|
| Title | Diagnostic Strategy of Pancreatic Cancer | |
| Publish Date | 2016/12 | |
| Author | Mitsuhiro Kida | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Takaaki Matsumoto | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Eiji Miyata | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Toru Kaneko | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Hiroshi Yamauchi | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Kosuke Okuwaki | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Tomohisa Iwai | Department of Gastroenterolgy, Kitasato University School of Medicine |
| Author | Hiroshi Imaizumi | Department of Gastroenterolgy, Kitasato University School of Medicine |
| [ Summary ] | The 5‒year survival rate of patients with pancreatic cancer is only 7 % ; therefore, its incidence is nearly equal to its mortality rate. The early diagnosis of pancreatic cancer is important for improving the survival rate. Therefore, periodic follow‒up examination of patients with risk factors such as a family history of pancreatic cancer, hereditary pancreatic cancer syndrome, diabetes mellitus, chronic pancreatitis, IPMN, or obesity, is necessary. Furthermore, patients with epigastralgia, dilatation of the pancreatic duct, and pancreatic cysts should be examined via endoscopic ultrasound (EUS), computed tomography (CT), and/or magnetic resonance cholangiopancreatography (MRCP). Although endoscopic retrograde cholangiopancreatography (ERCP) and EUS‒fine needle aspiration (FNA) are ideal for the histological diagnosis of pancreatic cancer, they carry risks of pancreatitis and seeding, respectively. Therefore, these procedures should be performed only after obtaining consent from patients. | |